TAKEDA PHARMACEUTICAL CO LTD (TAK) relative valueRV
TAK's operating margin of 7.5% ranks in the 48th percentile of 19 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2024-12-31 and 2025-12-31.
Kresmion ranks TAK against its industry peers from annual SEC filings and market-price snapshots.
Against 21 Drug Manufacturers - Specialty & Generic peers
| Metric | TAK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.6T JPY | n/a | n/a | n/a |
| Revenue YoY | 7.5% | 2.0% | 56th | 7 |
| Gross margin | 65.5% | 55.4% | 79th | 20 |
| Operating margin | 7.5% | 11.2% | 48th | 19 |
| Net margin | 2.4% | -3.4% | 55th | 20 |
| Return on equity | 1.6% | -3.5% | 58th | 17 |
| P / E | n/a | n/a | n/a | 4 |
| 1 year | n/a | n/a | n/a | n/a |
Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal periods ending between 2024-12-31 and 2025-12-31. Prices as of 2026-10-28. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001395064-25-000095
Peer set, 21 companies
HLN, RDY, ELAN, KNSA, INDV, RGC, HCM, PBH, CURLF, PRGO, TRLV, ALVO, ETON, GTBIF, CRON, HROW, EVO, AQST, EOLS, KMDA, VREOF
Left out: GALDY (no annual filing), JHPCY (no annual filing), SGIOF (no annual filing), HYPMY (no annual filing).
What could not be compared
- 22 The price series does not reach back to the start of this window.
- 20 Reported in a different currency than the subject. A level in another currency is not comparable and is not converted here.
- 20 The filer did not report this line in the filing used.
- 11 The denominator is zero or negative, so the ratio has no meaning.
- 9 This filer reports an ordinary share count and trades as a depositary receipt at a ratio Kresmion does not store, so price times shares would be wrong.
- 4 No annual filing (10-K, 20-F or 40-F) with fiscal-year figures.
- 3 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
- 1 The latest close times the filed share count disagrees with the company's market cap by more than a split-sized factor, so price and the filing are not on one share basis.
Free account
Open the relative value desk with a free account
An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, and the filing behind every cell. The table above stays free.
Cite this data
Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's industry group: the GICS sub-industry where the company is GICS-classified, otherwise the data vendor's industry label (the two label sets are not merged). A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.
Upstream: SEC EDGAR XBRL company facts
Kresmion, "TAK relative value, Kresmion", data as of 2025-06-25, https://kresmion.com/tools/relative-value/TAK. Upstream data: SEC EDGAR XBRL company facts.
Link to this data (HTML):
<a href="https://kresmion.com/tools/relative-value/TAK">TAK relative value, Kresmion (Kresmion)</a>